Leadgene Biomedical, Inc. has acquired CYTENA BPS for an undisclosed amount, marking a significant expansion of Leadgene’s capabilities in the bioprocessing and cell line development sectors. This transaction formally transfers ownership of CYTENA BPS, a company recognized for its advanced high-throughput microbioreactor technology, to Leadgene, rather than representing a funding round.
CYTENA BPS specializes in providing solutions for early-stage cell line development. Its flagship product, c.bird™, is a high-throughput microbioreactor that enables parallel cultivations in 96/24 well plates, miniaturizing production bioreactor environments to a 150-1600 µI scale. This technology is critical for accelerating the identification of high-producing and stable cell clones, thereby streamlining the cell line development workflow and reducing extensive efforts associated with later scaling-up processes. CYTENA BPS's portfolio also includes other microplate culture systems, serving applications such as high-yield protein and virus production, and drug screening.
This strategic acquisition positions Leadgene Biomedical, Inc., a company operating within the broader biomedical field, to integrate advanced bioprocessing tools directly into its offerings. The addition of CYTENA BPS’s innovative microbioreactor technology is expected to enhance Leadgene's research and development capabilities, particularly in areas requiring efficient cell culture and biopharmaceutical production. For Leadgene, this move represents a direct investment in biotechnological infrastructure that can accelerate internal projects and broaden its service portfolio.
The synergy between the two entities is anticipated to drive efficiency and innovation. By combining Leadgene's existing biomedical expertise with CYTENA BPS's specialized platforms, the integrated organization aims to offer more comprehensive solutions for biopharmaceutical companies, academic institutions, and research laboratories. This integration will allow for faster progression from early discovery to scalable production, impacting areas from therapeutic protein manufacturing to viral vector development.
Looking forward, the combined entity is poised to solidify its position in the life sciences market by providing integrated, high-throughput solutions that address critical bottlenecks in bioprocess development. The acquisition is set to foster continued technological advancement and deliver enhanced value to customers seeking optimized cell culture and bioprocessing workflows.